Assertio Research Development vs Total Revenue Analysis

ASRT Stock

USD 1.01 0.07 7.45%

Assertio Therapeutics financial indicator trend analysis is way more than just evaluating Assertio Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Assertio Therapeutics is a good investment. Please check the relationship between Assertio Therapeutics Research Development and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Research Development vs Total Revenue

Research Development vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Assertio Therapeutics Research Development account and Total Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Assertio Therapeutics' Research Development and Total Revenue is 0.6. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Assertio Therapeutics, assuming nothing else is changed. The correlation between historical values of Assertio Therapeutics' Research Development and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Assertio Therapeutics are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Research Development i.e., Assertio Therapeutics' Research Development and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.6

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Research Development

Total Revenue

Total revenue comprises all receipts Assertio Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Assertio Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Assertio Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assertio Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.At this time, Assertio Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 81.8 M in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (0.19).

	2021	2022	2023	2024 (projected)
Gross Profit	95.2M	137.5M	125.0M	112.5M
Total Revenue	111.0M	156.2M	152.1M	128.0M

Gross Profit Total Revenue

Assertio Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Cash	Cash And Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Short Term Investments	Common Stock	Other Assets	Long Term Debt	Property Plant Equipment
Total Assets		0.91	-0.73	0.79	0.75	0.88	0.73	0.3	0.6	0.94	0.21	0.83	-0.25	0.28	0.98	0.6	0.85	0.44	0.42	0.98	-0.29	0.48	0.55	-0.13	0.96	0.87
Short Long Term Debt Total	0.91		-0.92	0.71	0.59	0.87	0.79	0.42	0.67	0.91	0.3	0.77	-0.4	0.07	0.91	0.4	0.93	0.26	0.25	0.93	-0.43	0.65	0.63	-0.19	0.95	0.86
Other Current Liab	-0.73	-0.92		-0.5	-0.49	-0.68	-0.67	-0.43	-0.8	-0.75	-0.3	-0.62	0.34	0.11	-0.74	-0.29	-0.93	-0.18	-0.18	-0.76	0.42	-0.75	-0.54	0.18	-0.82	-0.68
Total Current Liabilities	0.79	0.71	-0.5		0.31	0.65	0.77	-0.1	0.34	0.85	0.42	0.88	-0.1	0.26	0.85	0.2	0.55	0.04	0.0	0.79	-0.04	0.1	0.32	0.07	0.77	0.65
Total Stockholder Equity	0.75	0.59	-0.49	0.31		0.61	0.22	0.39	0.57	0.52	-0.17	0.54	-0.06	0.17	0.6	0.86	0.71	0.76	0.76	0.65	-0.22	0.62	0.5	-0.13	0.63	0.57
Property Plant And Equipment Net	0.88	0.87	-0.68	0.65	0.61		0.64	0.46	0.45	0.82	0.11	0.64	-0.45	0.21	0.88	0.54	0.76	0.42	0.4	0.91	-0.52	0.48	0.69	-0.19	0.85	0.99
Net Debt	0.73	0.79	-0.67	0.77	0.22	0.64		0.05	0.38	0.91	0.68	0.73	-0.23	0.35	0.82	-0.08	0.59	-0.25	-0.27	0.8	-0.09	0.13	0.2	-0.16	0.86	0.65
Retained Earnings	0.3	0.42	-0.43	-0.1	0.39	0.46	0.05		0.29	0.17	-0.38	-0.07	-0.85	-0.37	0.25	0.44	0.47	0.49	0.51	0.37	-0.93	0.64	0.66	-0.15	0.32	0.5
Accounts Payable	0.6	0.67	-0.8	0.34	0.57	0.45	0.38	0.29		0.54	0.25	0.42	-0.14	-0.02	0.56	0.42	0.77	0.36	0.36	0.58	-0.22	0.72	0.37	-0.02	0.62	0.45
Non Current Assets Total	0.94	0.91	-0.75	0.85	0.52	0.82	0.91	0.17	0.54		0.47	0.84	-0.22	0.33	0.97	0.28	0.76	0.11	0.08	0.96	-0.19	0.32	0.4	-0.11	0.96	0.82
Non Currrent Assets Other	0.21	0.3	-0.3	0.42	-0.17	0.11	0.68	-0.38	0.25	0.47		0.31	0.13	0.58	0.3	-0.51	0.14	-0.62	-0.65	0.26	0.39	-0.19	-0.42	0.08	0.33	0.13
Net Receivables	0.83	0.77	-0.62	0.88	0.54	0.64	0.73	-0.07	0.42	0.84	0.31		0.05	0.22	0.83	0.34	0.71	0.15	0.11	0.79	-0.01	0.27	0.37	0.01	0.83	0.63
Common Stock Shares Outstanding	-0.25	-0.4	0.34	-0.1	-0.06	-0.45	-0.23	-0.85	-0.14	-0.22	0.13	0.05		0.26	-0.28	-0.18	-0.34	-0.21	-0.22	-0.37	0.89	-0.4	-0.53	0.03	-0.33	-0.52
Other Current Assets	0.28	0.07	0.11	0.26	0.17	0.21	0.35	-0.37	-0.02	0.33	0.58	0.22	0.26		0.29	0.01	-0.01	-0.1	-0.13	0.26	0.5	-0.34	-0.43	0.17	0.23	0.21
Total Liab	0.98	0.91	-0.74	0.85	0.6	0.88	0.82	0.25	0.56	0.97	0.3	0.83	-0.28	0.29		0.46	0.81	0.31	0.28	0.99	-0.28	0.39	0.51	-0.12	0.97	0.87
Total Current Assets	0.6	0.4	-0.29	0.2	0.86	0.54	-0.08	0.44	0.42	0.28	-0.51	0.34	-0.18	0.01	0.46		0.57	0.97	0.97	0.51	-0.35	0.59	0.59	-0.11	0.43	0.51
Short Term Debt	0.85	0.93	-0.93	0.55	0.71	0.76	0.59	0.47	0.77	0.76	0.14	0.71	-0.34	-0.01	0.81	0.57		0.46	0.45	0.84	-0.42	0.79	0.59	-0.16	0.87	0.75
Cash	0.44	0.26	-0.18	0.04	0.76	0.42	-0.25	0.49	0.36	0.11	-0.62	0.15	-0.21	-0.1	0.31	0.97	0.46		0.99	0.36	-0.4	0.55	0.55	-0.1	0.28	0.4
Cash And Short Term Investments	0.42	0.25	-0.18	0.0	0.76	0.4	-0.27	0.51	0.36	0.08	-0.65	0.11	-0.22	-0.13	0.28	0.97	0.45	0.99		0.33	-0.4	0.59	0.57	-0.12	0.25	0.37
Non Current Liabilities Total	0.98	0.93	-0.76	0.79	0.65	0.91	0.8	0.37	0.58	0.96	0.26	0.79	-0.37	0.26	0.99	0.51	0.84	0.36	0.33		-0.37	0.45	0.55	-0.14	0.97	0.9
Other Stockholder Equity	-0.29	-0.43	0.42	-0.04	-0.22	-0.52	-0.09	-0.93	-0.22	-0.19	0.39	-0.01	0.89	0.5	-0.28	-0.35	-0.42	-0.4	-0.4	-0.37		-0.56	-0.77	0.12	-0.32	-0.57
Short Term Investments	0.48	0.65	-0.75	0.1	0.62	0.48	0.13	0.64	0.72	0.32	-0.19	0.27	-0.4	-0.34	0.39	0.59	0.79	0.55	0.59	0.45	-0.56		0.72	-0.17	0.48	0.47
Common Stock	0.55	0.63	-0.54	0.32	0.5	0.69	0.2	0.66	0.37	0.4	-0.42	0.37	-0.53	-0.43	0.51	0.59	0.59	0.55	0.57	0.55	-0.77	0.72		-0.22	0.52	0.68
Other Assets	-0.13	-0.19	0.18	0.07	-0.13	-0.19	-0.16	-0.15	-0.02	-0.11	0.08	0.01	0.03	0.17	-0.12	-0.11	-0.16	-0.1	-0.12	-0.14	0.12	-0.17	-0.22		-0.2	-0.08
Long Term Debt	0.96	0.95	-0.82	0.77	0.63	0.85	0.86	0.32	0.62	0.96	0.33	0.83	-0.33	0.23	0.97	0.43	0.87	0.28	0.25	0.97	-0.32	0.48	0.52	-0.2		0.85
Property Plant Equipment	0.87	0.86	-0.68	0.65	0.57	0.99	0.65	0.5	0.45	0.82	0.13	0.63	-0.52	0.21	0.87	0.51	0.75	0.4	0.37	0.9	-0.57	0.47	0.68	-0.08	0.85

Click cells to compare fundamentals

Assertio Therapeutics Account Relationship Matchups

Assertio Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	527.2M	303.3M	326.5M	413.9M	286.4M	336.5M
Short Long Term Debt Total	351.3M	84.1M	73.5M	66.9M	40.9M	38.9M
Other Current Liab	2.1M	103.3M	114.2M	88.5M	79.1M	83.0M
Total Current Liabilities	184.6M	132.7M	135.0M	95.3M	93.4M	72.3M
Total Stockholder Equity	58.0M	55.5M	102.4M	225.7M	138.0M	93.7M
Property Plant And Equipment Net	3.5M	2.4M	1.5M	744K	2.0M	1.9M
Net Debt	309.2M	63.3M	36.7M	1.9M	(32.5M)	(30.9M)
Retained Earnings	(399.8M)	(427.9M)	(429.2M)	(319.6M)	(651.5M)	(619.0M)
Accounts Payable	16.2M	14.8M	6.7M	6.0M	13.4M	15.6M
Non Current Assets Total	423.2M	209.0M	223.0M	281.7M	115.4M	203.4M
Non Currrent Assets Other	6.1M	4.9M	5.5M	2.4M	2.0M	2.1M
Net Receivables	42.7M	44.4M	44.4M	45.4M	47.7M	26.3M
Common Stock Shares Outstanding	17.7M	26.2M	43.2M	54.7M	71.0M	74.6M
Liabilities And Stockholders Equity	527.2M	303.3M	326.5M	413.9M	286.4M	336.5M
Other Current Assets	15.7M	34.8M	29.7M	16.5M	24.2M	25.5M
Total Liab	469.2M	247.8M	224.1M	188.2M	148.4M	242.8M
Total Current Assets	104.0M	94.3M	103.5M	132.3M	171.1M	133.1M
Short Term Debt	80M	14.6M	14.2M	871K	928K	881.6K
Cash	42.1M	20.8M	36.8M	64.9M	73.4M	80.2M
Cash And Short Term Investments	42.1M	20.8M	36.8M	64.9M	73.4M	95.5M
Non Current Liabilities Total	284.7M	115.1M	89.1M	92.9M	55.0M	52.2M
Other Stockholder Equity	457.8M	483.4M	531.6M	545.3M	789.5M	829.0M
Common Stock	8K	13K	4K	5K	9K	8.6K
Other Assets	3.3M	206.6M	5.5M	82.5M	1.0	0.95
Long Term Debt	271.3M	72.2M	61.3M	66.4M	38.2M	36.3M
Property Plant Equipment	3.5M	4.8M	1.5M	881K	1.0M	962.5K
Current Deferred Revenue	(2.4M)	86.3M	96.5M	67.4M	77.5M	42.0M
Common Stock Total Equity	313.9M	6K	8K	13K	11.7K	11.1K
Property Plant And Equipment Gross	3.5M	2.4M	1.5M	744K	6.7M	5.7M
Other Liab	8.6M	40.1M	27.8M	26.5M	23.8M	29.7M
Inventory	3.4M	11.7M	7.5M	13.7M	37.7M	39.6M
Net Tangible Assets	(342.6M)	(144.6M)	(113.6M)	27.7M	25.0M	26.2M
Non Current Liabilities Other	13.4M	42.9M	27.8M	26.5M	9.2M	8.8M
Intangible Assets	400.5M	200.1M	216.1M	198.0M	111.3M	105.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC